Late effects of treatment for early-stage Hodgkin's disease.

por Brierley, J. D., Rathmell, A. J., Gospodarowicz, M. K., Sutcliffe, S. B., Munro, A., Tsang, R., Pintilie, M.
Publicado 1998

Analysis of the intra- and intertumoral heterogeneity of hypoxia in pancreatic cancer patients receiving the nitroimidazole tracer pimonidazole

por Dhani, N C, Serra, S, Pintilie, M, Schwock, J, Xu, J, Gallinger, S, Hill, R P, Hedley, D W
Publicado 2015

BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts

por Lohse, I, Borgida, A, Cao, P, Cheung, M, Pintilie, M, Bianco, T, Holter, S, Ibrahimov, E, Kumareswaran, R, Bristow, R G, Tsao, M-S, Gallinger, S, Hedley, D W
Publicado 2015

Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response

por Thoms, J W, Dal Pra, A, Anborgh, P H, Christensen, E, Fleshner, N, Menard, C, Chadwick, K, Milosevic, M, Catton, C, Pintilie, M, Chambers, A F, Bristow, R G
Publicado 2012

Hypoxia Marker GLUT-1 (Glucose Transporter 1) is an Independent Prognostic Factor for Survival in Bladder Cancer Patients Treated with Radical Cystectomy

por Boström, P.J., Thoms, J., Sykes, J., Ahmed, O., Evans, A., van Rhijn, B.W. G., Mirtti, T., Stakhovskyi, O., Laato, M., Margel, D., Pintilie, M., Kuk, C., Milosevic, M., Zlotta, A.R., Bristow, R.G.
Publicado 2016

Integrin α11β1 regulates cancer stromal stiffness and promotes tumorigenicity and metastasis in non-small cell lung cancer

por Navab, R, Strumpf, D, To, C, Pasko, E, Kim, K S, Park, C J, Hai, J, Liu, J, Jonkman, J, Barczyk, M, Bandarchi, B, Wang, Y H, Venkat, K, Ibrahimov, E, Pham, N-A, Ng, C, Radulovich, N, Zhu, C-Q, Pintilie, M, Wang, D, Lu, A, Jurisica, I, Walker, G C, Gullberg, D, Tsao, M-S
Publicado 2016